Navigation Links
BMJ and the Lupus Foundation of America to Publish Lupus Science & Medicine, the First Open Access Journal Dedicated to Lupus
Date:10/25/2013

Washington, DC (PRWEB) October 25, 2013

International knowledge healthcare provider BMJ and the Lupus Foundation of America (LFA) have announced that they have joined forces to publish the first open access journal dedicated to the poorly understood and potentially life threatening disease, lupus.

Lupus Science & Medicine will offer timely global access to the latest scientific advances in lupus. The title will officially launch early next year. Lupus Science & Medicine will be edited by Jill P Buyon, Division Director of Rheumatology, Professor of Medicine at New York University School of Medicine, and Ronald F van Vollenhoven, Professor and Chief, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID) The Karolinska Institute, Stockholm, Sweden.

Lupus research is currently published in a wide array of journals, particularly those in the specialties of rheumatology, immunology, dermatology and nephrology.

The new online title will offer scientists and clinicians a unique focal point
for new developments in the understanding and treatment of this complex and unpredictable autoimmune disease, the causes of which are still not clear.

Lupus represents a significant public health problem, affecting millions of people around the globe. In lupus the body’s immune system is out of balance, causing inflammation and tissue damage to any organ system in the body, including the skin, joints, heart and kidneys. Symptoms are varied and changeable, often mimicking other conditions, making lupus hard to diagnose and treat.

Lupus Science & Medicine is owned by the Lupus Foundation of America, and will be published by BMJ as a peer reviewed open access online title, with submissions on basic, clinical, translational, and epidemiological studies on all aspects of lupus and related diseases.

In common with the other open access titles, published by BMJ, the journal will enjoy fast editorial decisions and short publication times, bringing the latest research on lupus to a global audience.

Commenting on the new venture, BMJ Publishing Director Peter Ashman said:
"We are delighted that the Lupus Foundation of America has chosen BMJ as their publishing partner to launch this important and exciting new journal. The complexities of lupus mean that it deserves a dedicated platform for the publication of quality research and for discussion among clinicians, researchers and people with lupus.”

He continued, “BMJ's position as part of the global medical community, partnered with the Lupus Foundation of America’s decades of leadership in the field will ensure that this platform will help make strides towards finding cures for lupus.”

Sandra C Raymond, President and CEO of the Lupus Foundation of America, added: “Ten years ago, we developed Lupus Now, the first and only national publication devoted to addressing the complexities of living with lupus for people with the disease, their families, and care-givers.

With the advent of Lupus Science & Medicine, we are continuing our efforts to provide authoritative information on lupus to ensure that all stakeholders can easily access the latest research findings free of charge.”

Link to podcast by co-editor Ronald van Vollenhoven:

https://soundcloud.com/bmjpodcasts/what-to-expect-from-lupus/s-PIlxt

Link to podcast Lupus Foundation of America, CEO & President, Sandra C. Raymond

https://soundcloud.com/bmjpodcasts/bmj-and-the-lupus-foundation/s-Gpl8U

About BMJ

BMJ is a trusted global provider of evidence-based medical knowledge through its publications, which include more than 50 specialist titles and The BMJ, as well as online learning and decision support tools.

About the Lupus Foundation of America

The Lupus Foundation of America was founded in 1977. It is devoted to solving the mystery of lupus, one of the world’s cruelest, most unpredictable, and devastating diseases, while providing caring support to those who suffer from its brutal impact. The Foundation, and its nationwide network of chapters and support groups work to improve the quality of life for all those affected by lupus, through programs of research, education, and advocacy.

Further information on Lupus Science & Medicine can be found here: journals.bmj.com/site/lupus/

https://www.facebook.com/LupusFoundationofAmerica

https://twitter.com/LupusOrg

Read the full story at http://www.prweb.com/releases/2013/10/prweb11270004.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Exagen Diagnostics Launches Cutting-Edge Lupus Diagnostic
2. Lupus Research Institute Awards $3.6 Million for Novel Studies Driving Wide-Ranging New Science in Lupus
3. Karyopharm Therapeutics Announces Oral Presentation at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in preclinical models of Systemic Lupus Erythematosus (SLE)
4. A nanogel-based treatment for lupus
5. Lupus Research Institute Requests Strengthened NIH Funding for Biomedical Research in Debilitating Diseases like Lupus
6. Musculoskeletal Network Features New Research into the Cause of Rheumatoid Arthritis and Lupus
7. BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelonas Vall dHebron Hospital in Biomarker Research for Personalized Cancer Therapies
8. Leaders in Science Join Upcoming Celebration of the 100th Anniversary of the Oldest Science Foundation in America
9. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
10. Cord Blood America Announces Exclusive Agreement With National Childrens Leukemia Foundation to Store Stem Cells
11. Elsevier Foundation Awards 2011 Grants to Advance Women in Science and Support Libraries in Developing Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... 23, 2017  MIODx announced today that it ... immunotherapy technologies from the University of California, San ... to monitor a patient for response to immune ... The second license extends the technology with a ... to have an immune-related adverse event (IRAE) from ...
(Date:2/23/2017)... upscale Capitol Hill neighborhood, with its swanky shops, parks and cafés, ... treatment salon to set up shop. But there,s Hair ... bistro on E Madison Ave, and CEO Maria Botham ... clinic, we pride ourselves on being a destination for parents ... stigma associated with lice. Everyone can get lice – it ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... clearance to begin marketing the SPEAC® System, the Brain Sentinel® Seizure Monitoring and ... or in healthcare facilities during periods of rest. A lightweight, non-invasive monitor is ...
(Date:2/23/2017)... ... February 23, 2017 , ... David ... Inventors Recognition Reception at Purdue Research Park of West Lafayette, Indiana. ... recognition of outstanding contributions to, and success with, commercializing discoveries from Purdue research. ...
Breaking Biology Technology:
(Date:1/30/2017)... FRANCISCO , Jan. 30, 2017   Invitae ... the fastest growing genetic information companies, today announced that ... financial results and provide 2017 guidance on Monday, February ... conference call that day at 4:45 p.m. Eastern / ... Invitae,s management team will briefly review financial results, guidance, ...
(Date:1/24/2017)... Jan. 24, 2017  It sounds simple and ... that monitors vital signs and alerts parents on ... oxygen saturation level drops. But pediatric experts argue ... parents, with no evidence of medical benefits, especially ... marketed aggressively to parents of healthy babies, promising ...
(Date:1/18/2017)... 18, 2017  In vitro diagnostic (IVD) companies were ... acquisitions (M&A), and Kalorama Information expects that trend to ... been shifting. Generally, uncertainty in reimbursement and healthcare reform ... has changed the acquisitions landscape. Instead of looking to ... buying partners outside of their home country and also ...
Breaking Biology News(10 mins):